Skip to main content
SpringerLink
Log in

Economic Evaluation of Influenza Vaccination and Economic Modelling

Can Results Be Pooled?

  • Section 3: Economic Evaluation of Influenza Vaccination and Economic Modelling
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

Scientific reviewing methods were applied to economic studies of influenza vaccination, and an economic model of influenza vaccination was developed from these primary sources. Issues arising from the secondary literature review include the quality of evidence on the effectiveness of the vaccines, the absence of a traditional population-based approach to reviewing economic data, confusion in terminology, and how to generalise, from resource data contained in primary evaluations.

Data from the literature review were summarised in terms of resource units used in the prevention and treatment of influenza. An economic model was constructed using local unit costs (from the Emilia region of Italy) and applying the data to a notional population. The model was sensitive to length of stay in hospital but not to variation in incidence of influenza, days off work or number of medical consultations. The model was predicated on and is sensitive to an estimate of 80% vaccine effectiveness. The approach is constrained by the available data, but could be more generally useful in that it allows variations in the quantity of inputs to be considered separately from variations in their values. The model may be used locally as a decision-making tool, although the method needs further development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mulrow CD. Rationale for systematic reviews. In: Chalmers I and Altman DG, editors. Systematic reviews. BMJ Publishing Group, London: 1995: 1–8

    Google Scholar 

  2. Jefferson TO, Demicheli V. Is vaccination against hepatitis B efficient? A review of world literature. Health Economics 1994; 3: 25–38

    Article  PubMed  CAS  Google Scholar 

  3. Demicheli V, Casadio GP, Lanciotti G, et al. The Emilia costing study: valutazione dell’impatto economico della salmonellosiumana. Mecosan 1995; 11: 8–15

    Google Scholar 

  4. Elixhauser A, editor. Health care cost–benefit and cost–effectiveness analysis (CBAIEA). From 1979 to 1990: a bibliography. Medical Care 1993; 31 Suppl.: JS1–149

    Article  Google Scholar 

  5. Backhouse ME, Backhouse RJ, Edey SA. Economic evaluation bibliography. Health Economics 1992; 1 Suppl.: 1–235

    Google Scholar 

  6. Perez-Tirse J, Gross PA. Review of cost–benefit analyses of influenza vaccine. Pharmacoeconomics 1992; 2: 198–206

    Article  PubMed  CAS  Google Scholar 

  7. Schoenbaum SC, McNeil BJ, Kavet J. The swine–influenza decision. N Engl J Med 1976; 295: 759–65

    Article  PubMed  CAS  Google Scholar 

  8. Anonymous. Cost–effectiveness of flu vaccine. Congressional Office of Technology Assessment. Connecticut Medicine 1982; 46

    Google Scholar 

  9. Klarman HE, Guzick D. Economics of influenza. In: Selby P, editor. Influenza: virus, vaccines and strategy. New York: Academic Press Inc. 1976: 255–70

    Google Scholar 

  10. Evans DB, Hensley MJ, O’Connor SJ. Influenza vaccination in Australia: a review of the economic evidence for policy recommendations. Med J Aust 1988; 149: 540–3

    PubMed  CAS  Google Scholar 

  11. Anonymous. Prophylaxis viewed economically [translated from German]. Zahnartzliche Mitteilungen 1974; 19: 997–8

    Google Scholar 

  12. Fedson DS. The influenza vaccination demonstration project: an expanded policy goal. Infect Control Hosp Epidemiol 1990; 11 (7): 357–61

    Article  PubMed  CAS  Google Scholar 

  13. Helcl J, Gopfertova D, Heinz F. Economic relevance of influenza and other acute respiratory disease (translated from Czech). Czech Epidemiol 1988; 6: 340–9

    Google Scholar 

  14. Shevchenko LF, Sinyak KM, Sazhok RA, et al. Economic losses due to influenza and other acute respiratory illnesses and possibilities of reducing them (translated from Russian). 1974 (unpublished)

  15. Anonymous. Economic losses in influenza epidemics (translated from Czech). Czech Ministry of Health 1982 (unpublished)

    Google Scholar 

  16. Elo O. Cost–benefit studies of vaccination in Finland. International Symposium on Immunization: benefit versus risk factors,Brussels 1978. Dev Biologic Standards 1979; 43: 419–28

    CAS  Google Scholar 

  17. Kouznetsov VS, Gouzyukina TV, Orlova ER. L’efficence economique et medico’sociale des innovations et la pratiquede la protection de la sante’. Sante Publique 1990; 33: 11–6

    PubMed  CAS  Google Scholar 

  18. Fedson D. Clinical practice and public policy for influenza and pneumococcal vaccination for the elderly. Clin Geriatr Med 1992; 8: 183–99

    PubMed  CAS  Google Scholar 

  19. McBean AM, Babish D, Warren JL. The impact and cost of influenza in the elderly. Arch Intern Med 1993; 153: 2105–11

    Article  PubMed  CAS  Google Scholar 

  20. Fedson OS. Influenza and pneumococcal vaccination: clinical effectiveness, value to society and variations between countries in public policies and clinical practice. 1991 (unpublishedreview)

  21. Gasparin R. La vaccinazione antinfluenzale: stato dell’arte, esperienze e prospettive. Atti del Trentacinquesimo Congresso Nazionale di Igiene, 1992 (unpublished)

    Google Scholar 

  22. Kogan H. Flu vaccinations: are they worth the cost? Occup Health 1993; 45: 21–2

    CAS  Google Scholar 

  23. Eono P, Desfontaine M. Vaccinations en milieau militaire. Etude cout Jefficacite, 1993 (unpublished)

    Google Scholar 

  24. Hocking B. Benefits and costs of influenza immunization in the workforce. Asia Pacific Human Resource Management,November 1989; 87–93

    Google Scholar 

  25. Levy E, Levy P. La vaccination contre la grippe des personnes d’age actif (25-64 ans): une etude cout–benefice. Revue Epidemiol Sante Publique 1992; 40: 285–95

    CAS  Google Scholar 

  26. Patriarca PA, Arden NH, Koplan JP, et al. Prevention and control of type A influenza infections in nursing homes. Benefits and costs of four approaches using vaccination and amantadine. Ann Intern Med 1987; 107: 732–40

    PubMed  CAS  Google Scholar 

  27. Helliwell BE, Drummond MF. The costs and benefits of preventing influenza in Ontario’s elderly. Can J Public Health 1988; 79: 175–80

    PubMed  CAS  Google Scholar 

  28. Gavira FI, Lardinois R. Analisis de rentabilidad de la vacunacion antigripal en una poblacion rural (La Victoria, Cordoba). Med Clin (Barc) 1990; 94: 777–81

    CAS  Google Scholar 

  29. Maucher JM, Gambert SR. Cost–effective analysis of influenza vaccination in the elderly. Age 1990; 13: 81–5

    Article  Google Scholar 

  30. Smith JWG, Pollard R. Vaccination against influenza: a five year study in the Post Office. J Hyg 1979; 83: 157–80

    Article  CAS  Google Scholar 

  31. Riddiough MA, Sisk JE, Bell JC. Influenza vaccination: cost effectiveness and public policy. JAMA 1983; 249: 3189–95

    Article  PubMed  CAS  Google Scholar 

  32. Office of Technology Assessment, US Congress. Cost–effectiveness of influenza vaccination. Washington: Government Printing Office, 1982

  33. Kavet J. A perspective on the significance of pandemic influenza. Am J Public Health 1977; 67: 1063–70

    Article  PubMed  CAS  Google Scholar 

  34. Sauras IA. Analisis economico del coste de la gripa aplicado a la provincia de Huesca. Rev Sanit Hig Publica 1987; 61: 1017–28

    Google Scholar 

  35. Koplin AN, Francis BJ, Martin RJ, et al. Administrative costs of the influenza control program of 1976-1977 in Illinois. Med Care 1979; 17: 201–9

    Article  PubMed  CAS  Google Scholar 

  36. Mullooly JP, Bennett MD, Hornbrook MRP, et al. Influenza vaccination programs for elderly persons: cost–effectiveness in a health maintenance organization. Ann Intern Med 1994; 121: 947–52

    PubMed  CAS  Google Scholar 

  37. Koopmanschap MA, Rutten FH. Indirect costs in economic studies. Confronting the confusion. Pharmacoeconomics 1993; 4: 446–54

    Article  PubMed  CAS  Google Scholar 

  38. Servero CA, Fagnani F, Lafuma A. Cost–effectiveness of hepatitis Aprevention in France. Pharmacoeconomics 1995; 8 (1): 46–61

    Article  Google Scholar 

  39. Light RJ, Pillemer D. Summing up. The science of reviewing research. London: Harvard University Press, 1984

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ministry of Defence, Army Medical Directorate, Keogh Barracks, Hants GU12 5RR, Ash Vale, Hampshire, England

    Tom Jefferson

  2. University of Pavia, Pavia, Italy

    Vittorio Demicheli

Authors
  1. Tom Jefferson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vittorio Demicheli
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jefferson, T., Demicheli, V. Economic Evaluation of Influenza Vaccination and Economic Modelling. Pharmacoeconomics 9 (Suppl 3), 67–72 (1996). https://doi.org/10.2165/00019053-199600093-00015

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199600093-00015

Keywords

Search

Navigation